Deficiência e seus correlatos clínicos na hipertensão pulmonar medidos pelo World Health Organization Disability Assessment Schedule 2.0: um estudo prospectivo e observacional

Published on Jan 1, 2019in Jornal Brasileiro De Pneumologia1.371
· DOI :10.1590/1806-3713/e20170355
Abílio Reis4
Estimated H-index: 4
Mário Santos13
Estimated H-index: 13
+ 5 AuthorsNelson Pacheco da Rocha15
Estimated H-index: 15
(University of Aveiro)
  • References (21)
  • Citations (0)
#1Stefano Federici (University of Perugia)H-Index: 18
#2Marco Bracalenti (University of Perugia)H-Index: 2
Last. Juan V. LucianoH-Index: 24
view all 4 authors...
AbstractPurpose: This systematic review examines research and practical applications of the World Health Organization Disability Assessment Schedule (WHODAS 2.0) as a basis for establishing specific criteria for evaluating relevant international scientific literature. The aims were to establish the extent of international dissemination and use of WHODAS 2.0 and analyze psychometric research on its various translations and adaptations. In particular, we wanted to highlight which psychometric feat...
51 CitationsSource
#1Deborah H. McCollister (University of Colorado Denver)H-Index: 4
#2Shannon ShafferH-Index: 1
Last. Andrew J. PeacockH-Index: 45
view all 8 authors...
Regulators and clinical experts increasingly recognize the importance of incorporating patient-reported outcomes (PROs) in clinical studies of therapies for pulmonary arterial hypertension (PAH). No PAH-specific instruments have been developed to date in accordance with the 2009 FDA guidance for the development of PROs as endpoints in clinical trials. A qualitative research study was conducted to develop a new instrument assessing PAH symptoms and their impacts following the FDA PRO guidance. A ...
9 CitationsSource
#1Shuyan Gu (ZJU: Zhejiang University)H-Index: 5
#2Huimei Hu (ZJU: Zhejiang University)H-Index: 4
Last. Hengjin Dong (ZJU: Zhejiang University)H-Index: 6
view all 3 authors...
Abstract Background The increasing survival of patients with pulmonary arterial hypertension (PAH) has shifted attention towards the disease burden that PAH imposes on patients and healthcare systems. Most studies emphasize epidemiology and medications, while large observational studies reporting on the health-related quality of life (HRQOL) of patients with PAH are lacking. Objective Our objective was to study the HRQOL of patients with PAH and to summarize the factors that influence it. Method...
5 CitationsSource
#1Ryan J. AndersonH-Index: 2
#2Atul MalhotraH-Index: 76
Last. Nick H. KimH-Index: 24
view all 3 authors...
On May 16 th , 2016, Nick H. Kim, MD [University of California San Diego (UCSD), Division of Pulmonary, Critical Care & Sleep Medicine] delivered his keynote presentation outlining the current state of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). As the title underscores, the lecture is not simply an outline of current therapeutic strategies but is instead a blueprint detailing the historical foundation of the field, ongoing changes in clinical...
1 CitationsSource
#1Nazzareno GalièH-Index: 80
#2Marc HumbertH-Index: 119
Last. Marius M. HoeperH-Index: 79
view all 13 authors...
ALAT : alanine aminotransferase ASAT : aspartate aminotransferase APAH : associated pulmonary arterial hypertension BAS : balloon atrial septostomy BMPR2 : bone morphogenetic protein receptor 2 BNP : brain natriuretic peptide BPA : balloon pulmonary angioplasty BREATHE : Bosentan
1,884 CitationsSource
#1Marion Delcroix (Katholieke Universiteit Leuven)H-Index: 36
#2Luke Howard (Imperial College London)H-Index: 32
Pulmonary arterial hypertension (PAH) is a debilitating disease that pervades all aspects of a patient's daily life. It is also increasingly acknowledged that the burden of PAH extends to older patients and carers. Until recently, the adverse effect of disease symptoms on the physical, emotional and social factors governing patient health-related quality of life (HRQoL) remained largely unrecognised. With a shift in therapeutic objectives to longer term improvements and HRQoL benefits, clinical ...
31 CitationsSource
#1Caio Jcs Fernandes (USP: University of São Paulo)H-Index: 1
#2Barbara Cs Martins (USP: University of São Paulo)H-Index: 2
Last. Rogério Souza (USP: University of São Paulo)H-Index: 38
view all 8 authors...
Background Improvement in quality of life together with better survival are the ultimate goals in the treatment of pulmonary arterial hypertension (PAH) patients. The objective of this study was to evaluate the health-related quality of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify the prognostic implication of this assessment.
21 CitationsSource
#1Janelle Yorke (University of Manchester)H-Index: 19
#2Paul A. Corris (Freeman Hospital)H-Index: 60
Last. Iain Armstrong (Royal Hallamshire Hospital)H-Index: 10
view all 8 authors...
The aim of this study was to develop a measure of the impact of pulmonary hypertension (PH) on health-related quality of life (HRQoL) as there is a need for a short, validated instrument that can be used in routine clinical practice. Interviews were conducted with 30 PH patients to derive 32 statements, which were presented as a semantic differential six-point scale (0–5), with contrasting adjectives at each end. This item list was completed by patients attending PH clinics across the UK and Ire...
34 CitationsSource
#1Michael Halank (TUD: Dresden University of Technology)H-Index: 29
#2Franziska Einsle (TUD: Dresden University of Technology)H-Index: 17
Last. V. Köllner (Saarland University)H-Index: 11
view all 13 authors...
Background The objective of this prospective study was to evaluate the impact of exercise capacity, mental disorders, and hemodynamics on quality-of-life (QoL) parameters in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
31 CitationsSource
a b s t r a c t Background: Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pul- monary hypertension (CTEPH) experience impaired health-related quality of life (HRQL). The objective of this study was to evaluate HRQL in a nation-wide sample. Methods: This is a prospective, multicenter, non-interventional study of HRQL including 139 (89%) PAH and 17 (11%) CTEPH patients (women 70.5%; mean age, 52.2) recruited from 21 Spanish hospitals. 55% had idiopathic PAH, 34% ot...
24 CitationsSource
Cited By0